Amplia Therapeutics Ltd Asset Resilience Ratio
Amplia Therapeutics Ltd asset resilience ratio. Amplia Therapeutics Ltd (ATX) has an Asset Resilience Ratio of 65.46% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Amplia Therapeutics Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Amplia Therapeutics Ltd (2017–2025)
Asset resilience ratio of Amplia Therapeutics Ltd from 2017 to 2025. This chart shows how Amplia Therapeutics Ltd's Asset Resilience Ratio has changed over time. Read Amplia Therapeutics Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Amplia Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Amplia Therapeutics Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$29.16 Million | 65.46% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$29.16 Million | 65.46% |
Asset Resilience Insights
- Very High Liquidity: Amplia Therapeutics Ltd maintains exceptional liquid asset reserves at 65.46% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Amplia Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Amplia Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Amplia Therapeutics Ltd Asset Resilience Ratio by Year (2017–2025)
Amplia Therapeutics Ltd asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Amplia Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 47.36% | AU$10.86 Million ≈ $7.69 Million |
AU$22.94 Million ≈ $16.23 Million |
+24.56pp |
| 2024-03-31 | 22.80% | AU$3.39 Million ≈ $2.40 Million |
AU$14.85 Million ≈ $10.50 Million |
-19.92pp |
| 2023-03-31 | 42.73% | AU$7.98 Million ≈ $5.65 Million |
AU$18.68 Million ≈ $13.22 Million |
-0.67pp |
| 2022-03-31 | 43.39% | AU$10.62 Million ≈ $7.52 Million |
AU$24.48 Million ≈ $17.32 Million |
+26.40pp |
| 2021-03-31 | 16.99% | AU$1.85 Million ≈ $1.31 Million |
AU$10.88 Million ≈ $7.70 Million |
+4.84pp |
| 2020-03-31 | 12.16% | AU$1.11 Million ≈ $784.07K |
AU$9.12 Million ≈ $6.45 Million |
-1.35pp |
| 2019-03-31 | 13.50% | AU$1.24 Million ≈ $878.02K |
AU$9.19 Million ≈ $6.50 Million |
-59.61pp |
| 2018-03-31 | 73.11% | AU$1.93 Million ≈ $1.37 Million |
AU$2.64 Million ≈ $1.87 Million |
+10.17pp |
| 2017-03-31 | 62.94% | AU$4.74 Million ≈ $3.36 Million |
AU$7.54 Million ≈ $5.33 Million |
-- |
About Amplia Therapeutics Ltd
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develo… Read more